Promethera closes series B

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) raised EUR 17 million ($22.5 million) in a series B round and secured a EUR 6.6 million ($8.7 million) government loan from the Walloon region of Belgium. New investors Boehringer Ingelheim Venture Fund; the venture arm of Shire plc (LSE:SHP; NASDAQ:SHPGY); Mitsui Global Investment; ATMI (NASDAQ:ATMI); and Sambrinvest participated in the round. Promethera's existing investors are Vesalius Biocapital Partners; Société Régionale d'Investissement de Wallonie; Vives-Louvain Technology Fund; Life Science Research Partners; NivelInvest; Fianciere Spin-Off Luxembourgeoise; Sopartec; and angel investors. ...